Markets have had a volatile March so far as renewed inflation fears and the collapse of a Silicon Valley bank sent investors into risk-off mode. Stocks fell, with the Dow Jones Industrial Average falling for a fifth straight day on Monday, while the 2-year U.S. Treasury yield plunged. Meanwhile, the Cboe Volatility Index (VIX), Wall Street’s preferred gauge of fear, hit its highest level since late 2022 on Monday and approached territory considered high risk. It led some strategists – including Morgan Stanley’s Mike Wilson – to declare that the next phase of the bear market had begun. Against this backdrop, CNBC Pro used FactSet to screen stocks in the MSCI World Index and the S&P 500 that appear to be able to withstand volatility well and are poised to do well going forward. Screening criteria are: Low volatility levels, or a beta below 1.0; Estimated 2023 earnings growth above 10%; Average price target upside of at least 10%; At least 40% of analysts have Buy ratings on the stock. There is a mix of healthcare, consumer, utilities and even some financial stocks on the screen. Canadian financial services firm Fairfax Financial Holdings and Japanese natural gas provider Tokyo Gas top the list for expected earnings growth this year — both more than 150 percent. British bank HSBC also made the list, with earnings forecast to rise nearly 50 percent, compared with an average gain of 23 percent. HSBC was notable as it bought Silicon Valley Bank’s UK subsidiary this week, sending its shares lower. About 46% of analysts have buy ratings on the stock, according to FactSet. Ferrari, the Italian luxury sports car maker, hit the screens, with earnings expected to rise 21 percent, with room for about 20 percent upside. Morgan Stanley recently named Ferrari its top company-wide pick, replacing Tesla. Analyst Adam Jonas raised his price target on Ferrari by $30 to $310, suggesting the stock could rise 28% in the next year. Also on CNBC Pro screens were a slew of pharma or healthcare and consumer stocks. These include Danish pharmaceutical company Novo Nordisk, US company UnitedHealth and US chocolate maker Hershey. Singapore-based infrastructure group Keppel stood out with the highest potential upside of more than 50%.